Primary Biliary Cholangitis; cirrhosis; chronic autoimmune disease

CymaBay Therapeutics Announces Results of Global Phase 3 ENHANCE Study for Primary Biliary Cholangitis

Post author:Rose Duesterwald
Post published:November 17, 2020
Post category:Primary Biliary Cholangitis Rare Disease

CymaBay Therapeutics, a biopharmaceutical company based in Newark, CA, develops and provides access to novel therapies with a recent focus on primary biliary cholangitis (PBC). The company is currently developing…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More